Minority clinical trial enrollment remains one of the most persistent and consequential challenges in modern clinical research. At FOMAT, addressing this gap is not a secondary priority \u2014 it is the foundation of our entire operational model. With over 91 percent of our recruitment driven through community partnerships, we work every day to close the distance between underrepresented communities and the studies that need them.<\/p>\n
The FDA Safety and Innovation Act of 2012 formally established the inclusion of minorities as a core value in clinical research regulation. The reasoning is straightforward: treatments and medicines frequently work differently across demographic groups, and data gathered exclusively from homogeneous populations produces incomplete and sometimes misleading results.<\/p>\n
Despite this regulatory mandate, minorities continue to account for fewer than 10 percent of patients enrolled in clinical trials. Hispanics, who represent over 17 percent of the U.S. population, participate at a rate of just 7.6 percent in NIH sponsored research and only 3 percent in industry sponsored studies. Closing this gap requires understanding exactly why minority clinical trial enrollment remains so low.<\/p>\n
1. Low Awareness Among Patients<\/strong> Research consistently shows that minorities are as willing to participate in clinical trials as white patients but they are simply not asked. Awareness of available studies, eligibility criteria, and the potential personal and societal benefits of participation remains critically low in many communities.<\/p>\n 2. Distrust of Medical Institutions<\/strong> Trust is among the most significant barriers to minority clinical trial enrollment. African American communities in particular carry a well documented history of exploitation in medical research, creating deeply rooted skepticism toward clinical institutions. According to the National Institutes of Health<\/a>, participants have expressed fear that physicians would not be honest about study risks, and many describe concerns about being treated as test subjects rather than patients.<\/p>\n 3. Physician Bias<\/strong> Literature consistently identifies physician bias as a structural contributor to low minority clinical trial enrollment. Research shows that physicians are statistically less likely to recommend clinical trial participation to minority patients, and that false perceptions about minority patients’ willingness or ability to comply with protocols affect enrollment decisions before patients are ever given the opportunity to decide for themselves.<\/p>\n 4. Limited Access to Care<\/strong> Many minority communities have historically had poor access to healthcare infrastructure. Studies indicate that a significant portion of disenfranchised minorities receive care exclusively in emergency room settings, where continuity of care is limited and enrollment in clinical trials is rarely discussed. Lack of health insurance further restricts access to facilities where trials are conducted.<\/p>\n 5. Geographic and Logistical Barriers<\/strong> Transportation, work schedules, childcare responsibilities, and trial site locations create practical obstacles that disproportionately affect minority clinical trial enrollment. Sites concentrated in academic medical centers often fail to reach the communities where minority patients actually receive care.<\/p>\n 6. Language and Cultural Barriers<\/strong> Clinical trial materials, informed consent documents, and study communications are predominantly available in English. For Spanish speaking patients and other non-English speaking communities, language barriers create confusion, reduce trust, and effectively exclude eligible participants before enrollment conversations begin.<\/p>\n 7. Lack of Centralized Data<\/strong> The absence of centralized databases tracking demographic participation across clinical trials makes it difficult to measure progress, identify gaps, or hold sponsors accountable for diversity outcomes. Without reliable data, minority clinical trial enrollment remains systematically underestimated.<\/p>\n FOMAT Medical has built its recruitment infrastructure specifically around the communities most affected by these barriers. Our network of investigator sites operates within Hispanic, African American, and other underrepresented communities, supported by bilingual staff, community based outreach, and long term relationships with local healthcare providers.<\/p>\n Improving minority clinical trial enrollment is not achievable through awareness campaigns alone \u2014 it requires structural change at the site level, sustained community trust, and a genuine commitment to reaching patients where they are. Learn more about how FOMAT approaches diversity in clinical research<\/a> and explore our active clinical studies<\/a> currently enrolling diverse patient populations across the United States.<\/p>\n","protected":false},"excerpt":{"rendered":" La participaci\u00f3n de las minor\u00edas en los ensayos cl\u00ednicos sigue siendo uno de los retos m\u00e1s persistentes y trascendentales de la investigaci\u00f3n cl\u00ednica moderna. En FOMAT, abordar esta brecha no es una prioridad secundaria, sino la base de todo nuestro modelo operativo. Con m\u00e1s del 91 por ciento\u2026<\/p>","protected":false},"author":3,"featured_media":111657,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[968],"tags":[918,1115,1183,915,914,906],"class_list":["post-7490","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates","tag-clinical-research","tag-clinical-research-diversity","tag-clinical-trial","tag-clinical-trials","tag-research","tag-trials"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/7490","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=7490"}],"version-history":[{"count":3,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/7490\/revisions"}],"predecessor-version":[{"id":111659,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/7490\/revisions\/111659"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/111657"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=7490"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=7490"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=7490"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}How FOMAT Addresses Minority Clinical Trial Enrollment<\/h3>\n